NASDAQ:LENZ LENZ Therapeutics (LENZ) Stock Price, News & Analysis $9.36 +0.29 (+3.14%) As of 12:26 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About LENZ Therapeutics Stock (NASDAQ:LENZ) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LENZ Therapeutics alerts:Sign Up Key Stats Today's Range$8.92▼$9.5450-Day Range$8.29▼$13.6852-Week Range$8.25▼$50.40Volume465,740 shsAverage Volume988,068 shsMarket Capitalization$293.28 millionP/E RatioN/ADividend YieldN/APrice Target$44.00Consensus RatingModerate Buy Company Overview LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California. Read More LENZ Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreLENZ MarketRank™: LENZ Therapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 568th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingLENZ Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialLENZ Therapeutics has a consensus price target of $44.00, representing about 375.9% upside from its current price of $9.25.Amount of Analyst CoverageLENZ Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about LENZ Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for LENZ Therapeutics are expected to grow in the coming year, from ($3.91) to ($2.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of LENZ Therapeutics is -3.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LENZ Therapeutics is -3.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLENZ Therapeutics has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about LENZ Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted32.47% of the float of LENZ Therapeutics has been sold short.Short Interest Ratio / Days to CoverLENZ Therapeutics has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.Change versus previous monthShort interest in LENZ Therapeutics has recently increased by 4.92%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLENZ Therapeutics does not currently pay a dividend.Dividend GrowthLENZ Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for LENZ Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for LENZ on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days.MarketBeat Follows9 people have added LENZ Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 800% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, LENZ Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders6.90% of the stock of LENZ Therapeutics is held by insiders.Percentage Held by Institutions54.32% of the stock of LENZ Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LENZ Therapeutics' insider trading history. Receive LENZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LENZ Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LENZ Stock News HeadlinesLENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor ConferenceMay 4 at 8:00 AM | globenewswire.comHC Wainwright Analysts Reduce Earnings Estimates for LENZApril 25, 2026 | americanbankingnews.comElon’s Biggest Launch Ever: 15x Bigger Than SpaceXThe Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked America's #1 stock picker in 2020. He was mentored by two hedge fund billionaires from the Soros network and trained at Caltech. His readers have had the chance to see gains as high as AMD +8,500%... Nvidia +5,000%... Tesla +3,500%... Palantir +1,000%... and Apple +890%.May 6 at 1:00 AM | InvestorPlace (Ad)Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), Maravai Lifesciences Holdings (MRVI) and LENZ Therapeutics (LENZ)April 22, 2026 | theglobeandmail.comLENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of ...April 20, 2026 | markets.businessinsider.comLENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United KingdomApril 20, 2026 | globenewswire.comLENZ Therapeutics (LENZ) price target decreased by 20.47% to 39.10April 9, 2026 | msn.comPresident of LENZ Therapeutics Picks Up 57% More StockApril 1, 2026 | finance.yahoo.comSee More Headlines LENZ Stock Analysis - Frequently Asked Questions How have LENZ shares performed this year? LENZ Therapeutics' stock was trading at $16.00 on January 1st, 2026. Since then, LENZ stock has decreased by 42.2% and is now trading at $9.2450. How were LENZ Therapeutics' earnings last quarter? LENZ Therapeutics, Inc. (NASDAQ:LENZ) posted its earnings results on Tuesday, March, 24th. The company reported ($1.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by $0.25. The business had revenue of $1.59 million for the quarter, compared to the consensus estimate of $3.09 million. Read the conference call transcript. When did LENZ Therapeutics IPO? LENZ Therapeutics (LENZ) raised $224 million in an initial public offering (IPO) on Thursday, June 24th 2021. The company issued 14,000,000 shares at a price of $15.00-$17.00 per share. Who are LENZ Therapeutics' major shareholders? LENZ Therapeutics' top institutional investors include C WorldWide Group Holding A S (2.23%), Y Intercept Hong Kong Ltd (0.51%), Bank of New York Mellon Corp (0.16%) and Hsbc Holdings PLC (0.07%). Insiders that own company stock include Ra Capital Management, LP, James W Mccollum and Shawn Olsson. View institutional ownership trends. How do I buy shares of LENZ Therapeutics? Shares of LENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of LENZ Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that LENZ Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V), JPMorgan Chase & Co. (JPM) and Netflix (NFLX). Company Calendar Last Earnings3/24/2026Today5/06/2026Next Earnings (Estimated)5/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 LENZ's financial health is in the Red zone, according to TradeSmith. LENZ has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LENZ Previous SymbolNASDAQ:LENZ CIK1815776 Webwww.graphitebio.com Phone650-484-0886FaxN/AEmployees110Year Founded2013Price Target and Rating Average Price Target for LENZ Therapeutics$44.00 High Price Target$67.00 Low Price Target$26.00 Potential Upside/Downside+370.3%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($2.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$82.13 million Net MarginsN/A Pretax Margin-427.62% Return on Equity-37.47% Return on Assets-35.13% Debt Debt-to-Equity RatioN/A Current Ratio14.23 Quick Ratio14.09 Sales & Book Value Annual Sales$19.09 million Price / Sales15.36 Cash FlowN/A Price / Cash FlowN/A Book Value$9.09 per share Price / Book1.03Miscellaneous Outstanding Shares31,350,000Free Float29,191,000Market Cap$293.28 million OptionableN/A Beta0.62 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:LENZ) was last updated on 5/6/2026 by MarketBeat.com Staff. From Our PartnersA U.S. Resource Gap Is a National Issue - and OpportunityAmerica still does not domestically produce one mineral tied to batteries, energy storage, and national defens...i2i Marketing Group, LLC | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredTrump and Elon are BACK15X Bigger Than SpaceX: Elon's New Launch While the rest of the market goes crazy for "the mother of all IP...InvestorPlace | SponsoredRevealed: The World’s First Trillion-Dollar RobotJensen Huang stood in Las Vegas and laid out Nvidia's vision for building the world's first trillion-dollar ro...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
